Novel mixed ligand di-n-butyltin(IV) complexes derived from acylpyrazolones and fluorinated benzoic acids: Synthesis, characterization, cytotoxicity and the induction of apoptosis in Hela cancer cells

• A series of dibutyltin(IV) complexes bearing both arylpyrazolone and fluorinated benzoate ligands, as antitumoral agents.
• High levels in vitro antitumoral activity against Hela and KB cancer cell lines.
• Compound 2 induces a higher apoptosis level in Hela cancer cells when compared to cisplatin.

Twenty one novel mixed ligand di-n-butyltin(IV) complexes [nBu2SnAL] (A = substituted 4-acyl-5-pyrazolone, and L = fluorinated benzoic acid) were prepared by condensation of di-n-butyltin(IV) oxide with HL and HA in 1:1:1 molar ratio in refluxing methanol. All of the complexes were characterized by elemental analyses, IR, NMR (1H, 13C, 119Sn) and in four cases by X-ray diffraction. Cytotoxicity of the compounds was studied against two human cancer cell lines (KB and Hela) by means of the MTT assay compared to cisplatin, featuring IC50 values in the low micromolar range. Hela cancer cell apoptosis-induced by 2 was examined by flow cytometry analysis, and preliminary results showed that 2 at concentrations of more than 1.0 μM can induce apoptosis.

Novel dibutyltin(IV) complexes bearing both acylpyrazolones and fluorinated benzoic acids were prepared and evaluated for in vitro antitumor activities. Hela cancer cell apoptosis-induced by one representative compound was examined.Figure optionsDownload as PowerPoint slide